Clinical trials: Aromatase Inhibitors
Breast Cancer
Acupuncture for Aromatase Inhibitor Induced Joint Pain
This is a randomized, controlled, pilot study to determine the safety and efficacy of acupuncture as an adjunct to pharmacological treatment compared to pharmacological intervention alone for the treatment of musculoskeletal pain…
- Trial name
- NCT00826397
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Columbia University
Poor Ovarian Response
Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study
Until now no scientific clinical evidence exists regarding the possible impact of long term endogenous androgen priming in IVF patients aligned with the Bologna Criteria, in specific the impact of priming on serum parameters…
- Trial name
- NCT03447184
- Testing
- Androgen priming
- Where
- Vietnam
- Volunteers
- 30 people
- Sponsor
- Mỹ Đức Hospital
Breast Cancer
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
This was a Phase II, multicenter, open-label, three-cohort, non-comparative study of alpelisib plus endocrine therapy (either fulvestrant or letrozole) in subjects (pre- and post-menopausal women and men) with HR-positive…
- Trial name
- BYLieve (NCT03056755)
- Testing
- Alpelisib, Fulvestrant, Letrozole
- Where
- 94 sites in United States, Argentina and 17 more
- Volunteers
- 383 people
- Sponsor
- Novartis Pharmaceuticals
Infertility Indicated for ICSI
Role of Aromatase Inhibitor to Enhance Ovulation in Poor Responder During Induction With Short Antagonist Protocol in Cases of ICSI
study the effect of aromataze inhibitor induction together with short stimulation protocol by gonadotrphin releasing hormon antagonist in cases that expected to be poor responder before ICSI
- Trial name
- AIPRICSI (NCT02741154)
- Testing
- induction with aromataze inhibitor, HMG, GnRh a
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Minia University
Mastectomy, Aromatase Inhibitors Therapy
Reverse Fly Exercise On Supraspinatus Tendinitis In Patients Receiving Aromatase Inhibitors Therapy After Mastectomy
Reverse Fly Exercise On Supraspinatus Tendinitis In Patients Receiving Aromatase Inhibitors Therapy After Mastectomy
- Trial name
- NCT07763080
- Testing
- Reverse fly excercise, Control group
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Metastatic Breast Cancer
Overcoming Endocrine Resistance in Metastatic Breast Cancer
Based on these results it can be envisioned that the majority of endocrine-responsive post-menopausal breast cancer patients will be treated with an AI as adjuvant therapy (front-line, switching or extending) and/or as first-line…
- Trial name
- OVER (NCT02394496)
- Testing
- Fulvestrant, Lapatinib, Aromatase Inhibitors
- Where
- 69 sites in Italy
- Volunteers
- 396 people
- Sponsor
- Consorzio Oncotech
Breast Cancer
Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients
This study is a prospective, controlled phase IV clinical trial among postmenopausal patients with hormone receptor-positive breast cancer.The main purpose is to compare the effects of steroidal aromatase inhibitor (AI)…
- Trial name
- NCT02765373
- Testing
- Exemestane, Letrozole, Anastrozole
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Chinese Academy of Medical Sciences
HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
Although randomized controlled trials (RCTs) provide evidence of efficacy, generalization of these results to patients in the real-world setting is challenging, given RCTs are conducted in highly selected patient populations.
- Trial name
- Treat ER+ight (NCT02753686)
- Testing
- Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy
- Where
- 25 sites in Canada
- Volunteers
- 440 people
- Sponsor
- Novartis Pharmaceuticals
Ectopic Pregnancy
Evaluation of Different Doses of Letrozole in Ectopic Pregnancy
The utilization of letrozole at a daily dose of 10 mg for medical treatment of ectopic pregnancy considerably has a high success rate without imposing any serious side effects compared to daily 5mg letrozole.
- Trial name
- letrezole (NCT05198141)
- Testing
- Letrozole tablets, laparoscopic salpingectomy
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Zagazig University
HR+/HER2+ Early Breast Cancer
Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer
This prospective, response-adapted phase II study evaluates the efficacy and safety of neoadjuvant fovinaciclib in combination with aromatase inhibitors and dual HER2 blockade in patients with HR-positive/HER2-positive early…
- Trial name
- TAYLOR-003 (NCT07616427)
- Testing
- Fovinaciclib, Aromatase Inhibitors, Trastuzumab + Pertuzumab
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Endometriosis
Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence
The aromatase inhibitor (anastrazole) plus long acting GnRH agonist leuprolide acetate will be tested for the treatment of women with endometriosis recurrence compared with classical GnRH analog treatment.
- Trial name
- NCT01769781
- Testing
- anastrazole, GnRH analog alone
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Centre for Endocrinology and Reproductive Medicine, Italy
Breast Cancer
Progressive Relaxation Training in Breast Cancer Patients Receiving Aromatatase Inhibitor Therapy
This study evaluates the effects of progressive relaxation exercises on artralgia, quality of life and anxiety-deppression in breast cancer patients receiving aromatase inhibitor.
- Trial name
- PREBCA (NCT04163692)
- Testing
- Progressive relaxation exercises
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people
- Sponsor
- Hacettepe University
Breast Cancer
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
This trial is a Phase 2 neoadjuvant study evaluating ARV-471 or anastrozole in post-menopausal women with estrogen receptor positive/ human epidermal growth factor receptor 2 (ER+/HER2)- localized breast cancer.
- Trial name
- NCT05549505
- Testing
- ARV-471, Anastrozole, Surgical resection of breast tumor
- Where
- 49 sites in United States, Georgia and 2 more
- Volunteers
- 152 people
- Sponsor
- Arvinas Inc.
Breast Cancer
A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
This study is designed to evaluate the clinical effects of the addition of metronomic oral vinorelbine to letrozole and anastrozole.
- Trial name
- VICTORIANE (NCT02730091)
- Testing
- Letrozole, Anastrozole, Vinorelbine
- Where
- France
- Volunteers
- 98 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Breast Neoplasms
Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy
The purpose of this study is to follow safety and quality of life outcomes on patients switching from tamoxifen therapy to aromatase inhibitor therapy.
- Trial name
- TAMARA (NCT00784888)
- Testing
- Aromatase inhibitors
- Where
- 16 sites in Turkey (Türkiye)
- Volunteers
- 344 people
- Sponsor
- Pfizer
Obesity, Oligospermia
Aromatase Inhibitors in the Treatment of Male Infertility
Obesity is associated with an increase in blood levels of estrogen. Estrogen or "female hormone" is believed to have a negative effect on sperm production.
- Trial name
- NCT00440180
- Testing
- Anastrozole
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Utah
Metastatic Breast Cancer
Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study
Women with recurrent or metastatic breast cancer who are hormone receptor positive are candidates for first line hormonal therapy including aromatase inhibitors.
- Trial name
- CONCEPT (NCT04012918)
- Testing
- Capecitabine plus aromatase inhibitor, A.I.
- Where
- Egypt
- Volunteers
- 124 people
- Sponsor
- Ain Shams University
Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative
Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer
This phase IIA trial studies the side effects of ribociclib and aromatase inhibitor and how well they work in treating participants with hormone receptor positive breast cancer that has spread to other places in the body.
- Conditions
- Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT03477396
- Testing
- Aromatase Inhibitor, Laboratory Biomarker Analysis, Pharmacokinetic Study
- Where
- 9 sites in United States
- Volunteers
- 2 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, Aromatase Inhibitors
Prevalence and Risk Factors for Pain and Related Adverse Reactions Among Breast Cancer Survivors on Aromatase Inhibitors
We obtained the occurrence of pain sensation, pain mood, sleep, etc. during endocrine therapy in breast cancer patients through telephone follow-up, and analyzed risk factors through artificial intelligence
- Conditions
- Breast Cancer, Aromatase Inhibitors, Endocrine Therapy, Pain
- Trial name
- NCT05628077
- Testing
- No intervention
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Peking University People's Hospital
Inguinal Hernia Unilateral, Inguinal Hernia Bilateral
Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males
This is a prospective, single-center, two-arm Phase 1 safety and feasibility trial evaluating anti-estrogen therapy in men age 50 years and older with symptomatic unilateral inguinal hernias.
- Conditions
- Inguinal Hernia Unilateral, Inguinal Hernia Bilateral, Inguinal Hernia Without Obstruction or Gangrene, Inguinal Hernia, Without Mention of Obstruction or Gangrene
- Trial name
- RIGHT (NCT07604272)
- Testing
- Fulvestrant, Anastrozole (ARIMIDEX™)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University